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Arrhythmias, especially supraventricular arrhythmias, often complicate the clinical course during autologous
hematopoietic cell transplantation (AHCT). We wanted to determine the incidence and risk factors for cardiac
arrhythmias during AHCT. The study included 983 patients (median age, 58 years [range, 19 to 77]; 61% male)
who underwent AHCT between August 2006 and December 2010 at a single institution and for whom all
relevant medical records were available for review. AHCT was done for plasma cell disorders in 58% patients
and for lymphoma or leukemia in the remaining. Overall, 92 patients (9.4%) developed a supraventricular
tachyarrhythmia at a median of 9 days posttransplantation (range, 0 to 18) and with a median duration of less
than 1 day (range, <1 to 17 days). Atrial ﬁbrillation was the most common and seen in 71 patients (7%),
followed by atrial ﬂutter and supraventricular tachycardia in 12 (1%) and 8 (1%) patients, respectively. In
multivariate analysis, age older than 63 years, presence of premature supraventricular complexes or atrio-
ventricular conduction delay on pretransplantation electrocardiogram, and history of any prior arrhythmia
increased the risk of arrhythmia. Development of arrhythmia resulted in longer outpatient follow-up after
AHCT, with the median follow-up for those developing an arrhythmia of 22 days compared with 19 days for
the rest; P < .001. In conclusion, 9% of patients undergoing ASCT developed supraventricular arrhythmias
posttransplantation, and this risk was elevated among older patients, those with a prior history of arrhyth-
mias, and those with pretransplantation electrocardiographic abnormalities.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION commonly complicate the clinical course of these patients
Autologous hematopoietic cell transplantation (AHCT)
has become the standard of care for a variety of malignancies
and is also increasingly used for non-malignant acquired
disorders. Amongmore than 50,000 ﬁrst hematopoietic stem
cell transplantations reported for 2006 worldwide, the
leading indications were lymphoproliferative disorders
(54.5%), leukemia (33.8%), solid tumors (5.8%), and nonma-
lignant disorders (5.1%) [1]. Most of these transplantations
were performed in either Europe (48%) or North America
(36%), with AHCT constituting the majority. In the United
States, AHCT is performed most commonly for multiple
myeloma followed by the lymphomas. Although the process
has become considerably safer over the past 2 decades, high-
dose chemotherapy and AHCT can be associated with
signiﬁcant morbidity related to a variety of side effects [2-4].
One of the more serious complications of AHCT remains
cardiac toxicity. With the use of conventional pre-AHCT
clinical cardiac evaluation, major cardiotoxic events such
as heart failure, cardiac tamponade, and life-threatening
cardiac arrhythmias have been reported to be uncommon,
occurring in less than 1% of patients [5]. Arrhythmias,
especially supraventricular arrhythmias, however, moreedgments on page 1236.
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13.05.019[6-9]. This has been clear since the initial report in 1998 by
Olivieri et al., who reported 5 cases of atrial ﬁbrillation (AF)
in stem cell transplantation recipients after high-dose
melphalan [10]. Subsequent studies reported the occur-
rence of supraventricular arrhythmias in 4% to 10% of bone
marrow transplant recipients [6-9]. However, factors pre-
disposing to such arrhythmias have not been well studied to
date.
Although these arrhythmias are easily treatable in most
patients, they can still result in prolongation of hospital stay
and an increased rate of intensive care admissions. We
undertook this study to determine the incidence and risk
factors for cardiac arrhythmias during AHCT.METHODS
Following the approval from the Mayo Clinic Institutional Review Board,
we retrospectively analyzed the medical records of 1000 consecutive
patients who underwent AHCT for various malignancies between August
2006 and December 2010. All patients had given informed consent for the
use of their records for research purposes. Seventeen patients who had
AHCT for nonhematological malignancies and those who had incomplete
information regarding various parameters described below were excluded,
leaving 983 patients who met the criteria. Twenty-two of these 983 patients
received a combination of marrow and peripheral blood stem cell graft, and
all other patients received peripheral blood stem cells only. These patients
were managed by multidisciplinary teams on an outpatient basis and were
admitted to hospital as and when indicated [11]. Patients were seen on
a daily basis, or more often if needed, with daily monitoring of complete
blood count and chemistry with replacement of electrolytes and trans-
fusions as clinically indicated. Patients were not routinely placed on cardiac
monitoring of any nature irrespective of prior cardiac history.Transplantation.
Table 1
Baseline Characteristics
Characteristic N Percent
Patients 983 d
Age, yr (range) 58 (19-77)
Gender, men 603 61
Disease
Acute leukemia 10 2
Amyloidosis 140 14
Hodgkin disease 63 6
Myeloma 404 41
Non-Hodgkin lymphoma 337 34
POEMS 29 3
Conditioning
BEAM 395 40
Busulfan þ cytoxan 3 .3
Cytoxan þ TBI 10 1
Melphalan 565 58
ThioTEPA/BCNU (Carmustine) 1 .1
Zevalin/melphalan 8 .8
Medical comorbidities
Hypertension 372 37.8
CAD 75 7.6
Diabetes mellitus 105 10.6
Hypothyroidism 114 11.6
Hyperthyroidism 2 .2
Renal insufﬁciency 152 15.5
COPD 27 2.7
Obstructive sleep apnea 70 7.1
POEMS indicates polyneuropathy, organomegaly, endocrinopathy, mono-
clonal protein, skin changes; BEAM, carmustine (BCNU), etoposide, adria-
mycin, melphalan; TBI, total body irradiation; BCNU, Carmustine; COPD,
chronic obstructive pulmonary disease.
Figure 1. Time to onset of arrhythmia posttransplantation (Kaplan-Meier
estimate).
Table 2
Arrhythmia Characteristics (n ¼ 92)
Characteristics N Percent
Arrhythmia onset,
BMT day (range)
9 (0-18)
Duration, mean (range) <1 day (<1 to 17 days)
Type of arrhythmia
AF 71 78
Atrial Flutter 12 13
SVT 8 8
MAT 1 <1
Management
Treatment required 82 89
Beta-blockers 68 74
Calcium channel blockers 40 43
DC cardioversion 7 8
Outcome
Hypotension 33 36
Vasopressors 13 14
Recurrence 23 25
BMT indicates bone marrow transplantation; SVT, Supraventricular Tachy-
cardia; MAT, Multifocal Atrial Tachycardia; DC, Direct Current.
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weight, and clinical risk factors for atrial arrhythmia, including presence of
systemic hypertension, diabetes mellitus, coronary artery disease (CAD),
valvular heart disease, and thyroid diseases. Information regarding history
of arrhythmia was obtained from the medical records. Additionally, we also
reviewed the electrocardiographic records in our Mayo EKG Database for
any reports of arrhythmias or conduction abnormalities. All patients also
underwent transthoracic echocardiography before transplantation. The
echocardiographic data were electronically retrieved and reviewed for
parameters that could affect the risk of arrhythmias such as left ventricular
diastolic dysfunction, left ventricular ejection fraction, indexed left atrial
volume index, and valvular lesions.
Logistic regression was used to identify the best cut-point for contin-
uous variables, associated with the maximum risk of developing an
arrhythmia. The Kaplan-Meier method was used to estimate the median
time to onset of any arrhythmia, with patients not developing any
arrhythmia censored at the time of dismissal home post-AHCT. The Cox
proportional hazards model was used to estimate the risk associated with
various baseline factors. Patient-related variables included age; gender;
diagnosis; history of coexisting illnesses, such as CAD, hypertension, and
diabetes; prior history of arrhythmias; antiarrhythmic medications; or beta-
blocker use.
Cardiac parameters examined included left ventricular ejection fraction,
left atrial size, or presence of valvular abnormalities on echocardiogram, PR
interval, QTc interval, supraventricular complexes, or atrioventricular (AV)
conduction delays/blocks that included ﬁrst- and second-degree AV blocks
on pretransplantation electrocardiogram (ECG).
Transplantation-related factors examined include position of central line
tip (right atrium versus superior vena cava), conditioning regimen, neu-
tropenic fever, hypokalemia in the posttransplantation period, development
of mucositis, and diarrhea. All baseline variables were evaluated, and those
found to be signiﬁcantly associated with arrhythmia at P < .05 on univariate
analysis were then considered for multivariate analyses. All analyses were
performed using JMP 9.03 software (SAS Institute Inc., Cary, NC).
RESULTS
The median age of 983 patients who underwent AHCT
between August 2006 and December 2010 was 58 years
(range, 19 to 77), of which 61% were male. Among these
patients, 41% had myeloma, and, together with amyloidosis
and Polyneuropathy, organomegaly, endocrinopathy,monoclonal protein, skin changes (POEMS), plasma cell
disorders were the indication for transplantation in 58% of
patients, followed by lymphomas (40%), and acute leukemia
(2%) (Table 1). Eighty-two patients (8.3%) had a prior history
of arrhythmia, and 38 (3.9%) had a history of arrhythmia
during the month before transplantation. Eighteen patients
(.2%) had AF or ﬂutter at the start of transplantation. Two
hundred seven patients (21.1%) were on a beta-blockers, and
24 (2.4%) were on verapamil or diltiazem at the time of AHCT.
The median estimated duration to dismissal from outpatient
area to home hematologist (home-dismissal) post-
transplantation was 19 days (95% conﬁdence interval [CI], 19
to 20). Overall, 29 patients (3%) died during the 100 days
posttransplantation due to infectious causes, multiorgan
failure, pulmonary complications, and progressive disease in
15 patients and infection, multiorgan failure syndrome, acute
respiratory distress syndrome, and thromboembolic
complications in the remaining 14 patients.
Overall, 92 patients (9.4%) developed a symptomatic
supraventricular arrhythmia during the stem cell trans-
plantation course, at a median of 9 days posttransplantation
(range, 0 to 18). The cumulative incidence of symptomatic
arrhythmia in the posttransplantation period is shown in
Figure 1 (Kaplan-Meier estimate). AF was the most common
and was seen in 71 patients (7%), followed by atrial ﬂutter in
12 (1%) and supraventricular tachycardia in 8 (1%) (Table 2).
Figure 2. Median time to dismissal home after transplant (Kaplan-Meier
estimate). The median time to dismissal after transplant for patients devel-
oping an arrhythmia was 22 days as compared with 19 days for those who did
not develop an arrhythmia (P < .001).
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rhythm had normalized in 81 patients (88%) at the time of
dismissal posttransplantation, with a median duration of
arrhythmia of less than 1 day (range, <1 to 17 days). Eighty-
two patients 82 (89%) developing arrhythmia required
treatment, with most of them receiving a beta-blocker and/
or calcium channel blocker. Thirty-six percent of the patients
with an arrhythmia developed hypotension, but only 14%
required vasopressor support and 8% were electrically car-
dioverted during the peritransplantation period. Twenty-
three patients (25%) had recurrence of their arrhythmia
before dismissal at a median time of 12.5 days (range, 5 to
21). The median time to dismissal after transplantation for
patients developing an arrhythmia was 22 days as compared
with 19 days in those who did not (P < .001) (Figure 2).
We then examined various pre and peritransplantation
clinical and laboratory parameters to identify risk factors for
onset of supraventricular arrhythmias. In a univariate anal-
ysis, older age, presence of supraventricular complexes or AV
conduction delays such as ﬁrst -or second-degree AV block
on pretransplantation ECG, presence of any valvular abnor-
mality, presence of premature atrial complexes on ECG
pretransplantation, increased atrial size, history of hyper-
tension, history of CAD, any prior history of arrhythmia, or
being on a beta-blocker or antiarrhythmic agent all increased
the risk of developing a supraventricular arrhythmia afterTable 3
Univariate Comparisons of Patients with or Without Arrhythmia
Characteristics Arrhythmia
(n ¼ 92)
N Percen
Age > 63 yr 62 67
Prior history of arrhythmia 19 20
History of hypertension 47 51
History of CAD 15 16
Beta-blockers/antiarrhythmic at transplant 31 34
Electrocardiographic features
AV conduction delay or premature supraventricular
complexes
17 18.5
Echocardiographic characteristics
Atrium > 33 cc/m2 49 54
Presence of valvular abnormalities 12 13
Cox proportional hazards models. Bolded rows indicate variables signiﬁcant in mutransplantation (Table 3). We speciﬁcally examined the
relation between amyloid heart disease and risk of devel-
oping arrhythmia. Although there was a trend toward
increased risk in the presence of amyloid heart disease, this
was not signiﬁcant (P ¼ .08).
Using logistic regression, the best cut-off for age and for
atrial size in terms of risk of developing arrhythmia was
63 years and 33 cc/m2. However, in a multivariate analysis,
only age older than 63 years, presence of supraventricular
complexes or AV conduction delays on pretransplantation
ECG, and history of any prior arrhythmia increased the risk of
arrhythmia during transplantation. Among the patients with
age older than 63 years, presence of supraventricular
complexes or AV conduction delays on pretransplantation
ECG, and history of any prior arrhythmia, 20%, 26%, and 23%,
respectively, developed an arrhythmia compared with 4%,
8%, and 8%, respectively, among those without the risk
factors (P < 0.001 for each of the three comparisons).
Patients with 2 or more risk factors were at 12.7-fold (95% CI,
6.7 to 24) and those with 1 risk factor at 6.4-fold (95% CI, 3.8
to 11.3) higher risk of developing arrhythmia compared with
those with no risk factors (Figure 3). None of the underlying
hematological malignancies or medical comorbidities
impacted the risk of developing arrhythmia.DISCUSSION
Supraventricular arrhythmias are a well-recognized
complication after hematopoietic stem cell transplantation
[6-9]. The incidence of these complications was 9% in this
study, which is consistent with the previously reported
incidence of 4% to 10% [6-9]. However, none of the studies so
far, including ours, had patients on continuous cardiac
monitors, so the true incidence may be even higher.
AF was the most common arrhythmia and was present in
about 77% of patients developing an arrhythmia. The median
time at onset of arrhythmias was 9 days after AHCT, and this
is slightly later than the onset of between 3 and 7 days as
reported by earlier studies [6,8,9]. Most arrhythmias were
short lasting, however, with median duration of less than
a day. Interestingly, one fourth of these patients had
a recurrence of the arrhythmia at a median of 12.5 days, but
most patients (88%) were discharged in sinus rhythm.
Although a difference in mortality was not seen, these
arrhythmias were associated with an increase in the median
time to dismissal home from outpatient follow-up by 3 days.
Although well known, studies evaluating risk factors for
these arrhythmias are scarce. Most studies done so far haveControl Subjects
(n ¼ 891)
Risk Ratio (95% CI) P
t N Percent
246 28 4.8 (3.2-7.6) <.0001
63 7 3.2 (1.9-5.2) <.0001
325 36 1.7 (1.1-2.6) .01
60 7 2.5 (1.4-4.2) .003
183 21 1.9 (1.2-3.0) .005
49 5.5 3.2 (1.8-5.4) .0002
304 35 2 (1.3-3.1) .0008
55 6 2.2 (1.1-3.9) .02
ltivariate analysis.
Figure 3. Risk factors predicting development of arrhythmia post-
transplantation. Cumulative incidence curves for onset of arrhythmia after
transplant are shown. Patients with 2 or more risk factors were at 12.7-fold
(95% CI, 6.7 to 24) and those with one risk factor at 6.4-fold (95% CI, 3.8 to
11.3) higher risk of developing arrhythmia compared with those with no risk
factors.
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in predisposition to this risk [6,7,9]. Even in the general
population, the risk of developing AF increases with age,
with approximately 70% of patients with AF between ages 65
and 85 years [12]. Statistical analysis of our results showed
age older than 63 as amajor risk factor, with a risk ratio of 4.8.
Another predisposing factor emphasized in the multiple
studies is the use of chemotherapeutic agents. Among the
agents currently in use in transplantation patients, the
association of melphalanwith AF is themost well established
and has been implicated in a signiﬁcant proportion of
patients, including thosewithout any structural or functional
cardiac defects as well as those who are young [10]. Studies
have shown melphalan use to be associated with AF in 6.6%
to 11% of bone marrow transplantation patients, which is
signiﬁcantly higher than any other chemotherapeutic agent
[9,13-15]. Our study cohort was mainly composed of patients
with plasma cell disorders or lymphoma as the indication for
transplantation in most, and thus melphalan-free regimens
were given in only a few patients. Hence, the role of
melphalan could not be ascertained from our study.
History of arrhythmias was another predisposing factor
we observed in this study. Surprisingly, being on an antiar-
rhythmic agent was shown as a risk factor but only on
univariate analysis. This may reﬂect identiﬁcation of those
with history of arrhythmias. A predominance of older
patients in our study with multiple comorbidities requiring
the use of these agents may explain this ﬁnding. Similarly,
factors such as increased atrial size and history of hyper-
tension or CADwere found to be signiﬁcant on the univariate
model but not on the multivariate model. It is possible that
all these risk factors are inter-related and may be predis-
posing to atrial arrhythmias even before the transplantation.
More than one-half of our study group patients had
a plasma cell disorder. Whether the presence of cardiac
amyloidosis in these patients predisposes to arrhythmias has
always been a question. We found that although a higher
percentage of patients who developed supraventricular
arrhythmia had evidence of cardiac amyloidosis by echo-
cardiogram than the control subjects, the results were not
statistically signiﬁcant. However, at the same time, it must be
kept in mind that sensitivity of echocardiograms to detectearly cardiac involvement in amyloidosis tends to be low
even with recent advances [16-18].
Electrocardiographic changes such as AV conduction
delays (ﬁrst- or second-degree blocks) and Premature atrial
contractions were present in about 7% of patients during the
pretransplantation period, and their presence independently
predicted atrial arrhythmias posttransplantation. Both
frequent Premature atrial contractions and AV conduction
abnormalities have been previously shown to predict new AF
in the general population [19,20]. Several studies have
demonstrated the association between delayed intra-atrial
or interatrial conduction and increased risk of AF [21-23].
Although ﬁrst-degree AV block usually involves conduction
delay in the AV node, it is frequently accompanied by
abnormalities in other parts of the conduction system. In
addition, a prolonged PR interval can lead to delayed and
ineffective mitral valve closure and diastolic mitral regurgi-
tation, especially when the PR interval exceeds 230 ms. Early
asymptomatic cardiac amyloidosis predisposing to AV
conduction problems as well as posttransplantation AF could
be a possibility that will need further investigation [24-26].
Meanwhile, the presence of asymptomatic conduction blocks
or superior vena cava (SVC) on ECG even before stem cell
transplantations should not be disregarded.
In conclusion, among patients undergoing autologous
peripheral blood stem cell transplantation, the risk of
developing a supraventricular arrhythmia in the peri-
transplantation period is approximately 9%. The risk is higher
among older patients, those with a prior history of arrhyth-
mias, and those with electrocardiographic abnormalities
suggesting AV conduction delay and premature supraven-
tricular complexes. Although no association with increase in
mortality has been shown, these arrhythmias may warrant
additional management and can increase the time to
discharge, thereby increasing the cost of care. Identiﬁcation
of these high-risk patients may allow development of
speciﬁc interventions in future.ACKNOWLEDGMENTS
Financial disclosure: Supported in part by Mayo Clinic
Hematological Malignancies Program, Paul Calabresi K12
Award (CA96028).
Conﬂict of interest statement: S.K.K. has research support
for clinical trials from Celgene, Millennium, Novartis, and
Genzyme and is a consultant for Merck. A.D. and M.Q.L.
received clinical trial support from Celgene. None of these
fundings was used for the current study.
Authorship statement: A.S. and S.K.K. designed the study,
collected and analyzed the data, and wrote the manuscript.
W.J.H., S.M.A., F.K.B., D.D., A.D., D.A.G., M.A.G., S.R.H., D.J.I.,
P.B.J., M.Q.L., M.R.L., I.N.M., and L.F.P. contributed patients and
were involved in writing the manuscript.REFERENCES
1. Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell
transplantation: a global perspective. JAMA. 2010;303:1617-1624.
2. Jones JA, Qazilbash MH, Shih YC, et al. In-hospital complications of
autologous hematopoietic stem cell transplantation for lymphoid
malignancies: clinical and economic outcomes from the Nationwide
Inpatient Sample. Cancer. 2008;112:1096-1105.
3. Afessa B, Abdulai RM, Kremers WK, et al. Risk factors and outcome of
pulmonary complications after autologous hematopoietic stem cell
transplant hematopoietic stem cell transplant complications. CHEST J.
2012;141:442-450.
4. Gertz MA, Gastineau DA, Lacy MQ, et al. SCT without growth factor in
multiple myeloma: engraftment kinetics, bacteremia and hospitaliza-
tion. Bone Marrow Transplant. 2011;46:956-961.
A. Singla et al. / Biol Blood Marrow Transplant 19 (2013) 1233e1237 12375. Murdych T, Weisdorf DJ. Serious cardiac complications during bone
marrow transplantation at the University of Minnesota, 1977-1997.
Bone Marrow Transplant. 2001;28:283-287.
6. Hidalgo JD, Krone R, Rich MW, et al. Supraventricular tachyarrhythmias
after hematopoietic stem cell transplantation: incidence, risk factors
and outcomes. Bone Marrow Transplant. 2004;34:615-619.
7. Fatema K, Gertz MA, Barnes ME, et al. Acute weight gain and diastolic
dysfunction as a potent risk complex for post stem cell transplant atrial
ﬁbrillation. Am J Hematol. 2009;84:499.
8. Peres E, Levine JE, Khaled YA, et al. Cardiac complications in patients
undergoing a reduced-intensity conditioning hematopoietic stem cell
transplantation. Bone Marrow Transplant. 2010;45:149-152.
9. Feliz V, Saiyad S, Ramarao SM, et al. Melphalan-induced supraven-
tricular tachycardia: incidence and risk factors. Clin Cardiol. 2011;34:
356-359.
10. Olivieri A, Corvatta L, Montanari M, et al. Paroxysmal atrial ﬁbrillation
after high-dose melphalan in ﬁve patients autotransplanted with blood
progenitor cells. Bone Marrow Transplant. 1998;21:1049.
11. Gertz MA, Ansell SM, Dingli D, et al. Autologous stem cell transplant in
716 patients with multiple myeloma: low treatment-related mortality,
feasibility of outpatient transplant, and effect of a multidisciplinary
quality initiative. Mayo Clin Proc. 2008;83:1131-1138.
12. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused
updates incorporated into the ACC/AHA/ESC 2006 guidelines for the
management of patients with atrial ﬁbrillation: a report of the Amer-
ican College of Cardiology Foundation/American Heart Association
Task Force on Practice Guidelines developed in partnership with the
European Society of Cardiology and in collaboration with the European
Heart Rhythm Association and the Heart Rhythm Society. J Am Coll
Cardiol. 2011;57:e101-e198.
13. Moreau P, Milpied N, Mahé B, et al. Melphalan 220 mg/m2 followed by
peripheral blood stem cell transplantation in 27 patients with
advanced multiple myeloma. Bone Marrow Transplant. 1999;23:1003.14. Sirohi B, Powles R, Treleaven J, et al. The role of autologous trans-
plantation in patients with multiple myeloma aged 65 years and over.
Bone Marrow Transplant. 2000;25:533.
15. Phillips GL, Meisenberg B, Reece DE, et al. Amifostine and autologous
hematopoietic stem cell support of escalating-dose melphalan: a phase
I study. Biol Blood Marrow Transplant. 2004;10:473-483.
16. Rahman JE, Helou EF, Gelzer-Bell R, et al. Noninvasive diagnosis of
biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2004;43:410-415.
17. Selvanayagam JB, Hawkins PN, Paul B, et al. Evaluation and manage-
ment of the cardiac amyloidosis. J Am Coll Cardiol. 2007;50:2101-2110.
18. Banypersad SM, Moon JC, Whelan C, et al. Updates in cardiac
amyloidosis: a review. J Am Heart Assoc. 2012.
19. Chong BH, Pong V, Lam KF, et al. Frequent premature atrial complexes
predict new occurrence of atrial ﬁbrillation and adverse cardiovascular
events. Europace. 2012;14:942-947.
20. Perez MV, Dewey FE, Marcus R, et al. Electrocardiographic predictors of
atrial ﬁbrillation. Am Heart J. 2009;158:622.
21. Cheng S, Keyes MJ, Larson MG, et al. Long-term outcomes in individuals
with prolonged PR interval or ﬁrst-degree atrioventricular block. JAMA.
2009;301:2571-2577.
22. Dilaveris PE, Gialafos EJ, Sideris SK, et al. Simple electrocardiographic
markers for the prediction of paroxysmal idiopathic atrial ﬁbrillation.
Am Heart J. 1998;135:733-738.
23. Agarwal YK, AronowWS, Levy JA, Spodick DH. Association of interatrial
block with development of atrial ﬁbrillation. Am J Cardiol. 2003;91:882.
24. Reisinger J, Dubrey SW, Lavalley M, et al. Electrophysiologic abnor-
malities in AL (primary) amyloidosis with cardiac involvement. J Am
Coll Cardiol. 1997;30:1046-1051.
25. Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic ﬁndings
in primary systemic amyloidosis and biopsy-proven cardiac involve-
ment. Am J Cardiol. 2005;95:535-537.
26. Dubrey S, Hawkins P, Falk R. Amyloid diseases of the heart: assessment,
diagnosis, and referral. Heart. 2011;97:75-84.
